We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03710564
Brief Title: Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections (MERLIN)

First Submitted : October 16, 2018
First Submitted that Met QC Criteria : October 16, 2018
First Posted : October 18, 2018

Results First Submitted : June 28, 2022
Results First Submitted that Met QC Criteria : June 28, 2022
Results First Posted : July 22, 2022

Certification/Extension First Submitted : October 12, 2021
Certification/Extension First Submitted that Met QC Criteria : October 12, 2021
Certification/Extension First Posted : October 15, 2021

Last Update Submitted that Met QC Criteria : June 28, 2022
Last Update Posted : July 22, 2022